“…Aside from Candida auris, antifungal resistance is systematically led by non-albicans species in China (Zhang et al, 2020;Liu et al, 2021), South Korea (Kwon et al, 2021), Turkey (Guner Ozenen et al, 2023), Italy (Mazzanti et al, 2021), Thailand (Ngamchokwathana et al, 2021, and Saudi Arabia (Al-Dorzi et al, 2018), out of which, C. tropicalis represents the major contributor. Data on resistance/ susceptibility would appear to draw a trend of inverse sensitivity between compounds of the echinocandin group and fluconazole, with C. albicans displaying higher figures of resistance to echinocandin compounds than non-albicans species and lower figures of resistance to azole compounds than non-albicans species (Al-Dorzi et al, 2018;Jung et al, 2020;Guner Ozenen et al, 2023). Nevertheless, it has been reported that empirical administration of high-dose liposomal amphotericin B (L-AmB) is associated with better management of fungal invasiveness, less ICU-acquired candidemia, less need for an antifungal agent additional to L-AmB, and ultimately a reduction in ICU mortality, emphasizing the feasibility and relative safety of a preemptive antifungal therapy strategy to combat bloodstream Candida colonization (Azoulay et al, 2017).…”